<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478956</url>
  </required_header>
  <id_info>
    <org_study_id>CA40192</org_study_id>
    <secondary_id>2017-003649-10</secondary_id>
    <nct_id>NCT03478956</nct_id>
  </id_info>
  <brief_title>A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease</brief_title>
  <official_title>A Phase I, Open-Label, Randomized, Pharmacokinetic, Pharmacodynamic, And Safety Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients From 4 Years To Less Than 18 Years Of Age With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in
      pediatric patients of 4 to &lt;18 years of age with moderate to severe ulcerative colitis (UC)
      or with moderate to severe Crohn's disease (CD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">March 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration observed (Cmax) of Etrolizumab</measure>
    <time_frame>At pre-defined intervals from baseline through end of treatment (approximately 5 years).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration- time curve within a dosing interval (AUC-Tau) of Etrolizumab</measure>
    <time_frame>At pre-defined intervals from baseline through end of treatment (approximately 5 years).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (T1/2) of Etrolizumab</measure>
    <time_frame>At pre-defined intervals from baseline through end of treatment (approximately 5 years).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state concentration at the end of a dosing interval (Ctrough) of Etrolizumab</measure>
    <time_frame>At pre-defined intervals from baseline through end of treatment (approximately 5 years).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta 7 (B7) of Etrolizumab</measure>
    <time_frame>At pre-defined intervals from baseline through end of treatment (approximately 5 years).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Baseline to end of study (approximately 5 years).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibodies (ADAs) to Etrolizumab</measure>
    <time_frame>At pre-defined intervals from baseline through end of treatment (approximately 5 years).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients with Confirmed Progressive Multifocal Leukoencephalopathy (PML)</measure>
    <time_frame>At pre-defined intervals from baseline through end of treatment (approximately 5 years).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Low Frequency Etrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etrolizumab will be administered by subcutaneous (SC) injection every 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Frequency Etrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etrolizumab will be administered by SC injection every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrolizumab</intervention_name>
    <description>For Low Frequency Etrolizumab will be administered by SC injection 3mg/kg at week 0 and week 8 for a period of 16 weeks.
For High Frequency Etrolizumab will be administered by SC injection 1.5mg/kg at week 0,4,8 and 12 for a period of 16 weeks.</description>
    <arm_group_label>Low Frequency Etrolizumab</arm_group_label>
    <arm_group_label>High Frequency Etrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 4 years to &lt;18 years at the time of signing the Informed Consent Form.

          -  Weight of 13 kg or more

          -  Diagnosis of ulcerative colitis (UC) or Crohn's Disease (CD) confirmed by biopsy and
             established for &gt;=3 months (i.e., after first diagnosis by a physician according to
             American College of Gastroenterology [ACG] guidelines) prior to screening

          -  Inadequate response, loss of response or intolerance to prior immunosuppressants
             and/or corticosteroid treatment and/or anti-tumor necrosis factor (TNF) therapy

          -  For postpubertal females of childbearing potential: agreement to remain abstinent
             (refrain from heterosexual intercourse) or use acceptable contraceptive methods during
             the treatment period and for at least 24 weeks after the last dose of etrolizumab.

          -  For male patients: agreement to remain abstinent (refrain from heterosexual
             intercourse) or use contraceptive measures, and agreement to refrain from donating
             sperm

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Lack of peripheral venous access

          -  Congenital or acquired immune deficiency

          -  Neurological conditions or diseases that may interfere with monitoring for progressive
             multifocal leukoencephalopathy (PML)

          -  History of demyelinating disease

          -  History of cancer, including hematologic malignancy, solid tumors, and carcinoma in
             situ, within 5 years before screening

        Exclusion Criteria Related to Inflammatory Bowel Disease:

          -  Prior extensive colonic resection, subtotal or total colectomy, or planned surgery

          -  Past or present ileostomy or colostomy

          -  Diagnosis of indeterminate colitis

          -  Suspicion of ischemic colitis, radiation colitis, or microscopic colitis

          -  Diagnosis of toxic megacolon within 12 months of initial screening visit

          -  Abdominal abscess

          -  A history or current evidence of colonic mucosal dysplasia

          -  Patients with any stricture (stenosis) of the colon

          -  Patients with history or evidence of adenomatous colonic polyps that have not been
             removed

        Exclusion Criteria Related to Ulcerative Colitis

          -  Severe extensive colitis per investigator judgment that colectomy is imminent

        Exclusion Criteria Related to Crohn's Disease

          -  Sinus tract with evidence for infection (e.g., purulent discharge) in the clinical
             judgment of the investigator

          -  Short-bowel syndrome

          -  Evidence of abdominal or perianal abscess

          -  Expected to require surgery to manage CD-related complications during the study

        Exclusion Criteria Related to Prior or Concomitant Therapy

          -  Any prior treatment with anti-integrin agents (including natalizumab, vedolizumab, and
             efalizumab), ustekinumab, anti-adhesion molecules (e.g., anti-MAdCAM-1), or rituximab

          -  Use of IV steroids within 30 days prior to screening with the exception of a single
             administration of IV steroid

          -  Use of agents that deplete B or T cells (e.g., alemtuzumab or visilizumab) within 12
             months prior to Day 1, with the exception of AZA and 6-MP

          -  Use of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 4
             weeks prior to Day 1

          -  Use of other biologics (e.g. anti-TNF) within 8 weeks before dosing

          -  Chronic nonsteroidal anti-inflammatory drug (NSAID) use

          -  Patients who are currently using anticoagulants

          -  Apheresis (i.e., Adacolumn apheresis) within 2 weeks prior to Day 1

          -  Received any investigational treatment including investigational vaccines within 12
             weeks prior to Day 1 of the study or 5 half-lives of the investigational product,
             whichever is greater

          -  History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to
             chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or
             hypersensitivity to etrolizumab (active drug substance) or any of the excipients
             (L-histidine, L-arginine, succinic acid, polysorbate 20)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: CA40192 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Med Ctr; Pediatric Nephrology</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children'S National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CCMC Pediatric Gastroenterology Nutrition</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Health Specialty Center Park Cities</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Enfants Reine Fabiola</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen; Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski, Bartosz Korczowski</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Matki, Dziecka i Mlodziezy - przychodnia</name>
      <address>
        <city>Warszawa</city>
        <zip>00-632</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu; Servicio de Pediatria - Gastroenterologia y Nutricion</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Niño Jesus; Servicio de Pediatria - Gastrenterologia y Nutricion</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Materno Infantil de Malaga; Servicio de Pediatria, Gastroenterologia y Nutricion</name>
      <address>
        <city>Malaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital; The Childrens Department</name>
      <address>
        <city>London</city>
        <zip>E11BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Childrens Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheffield Childrens Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S102TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

